T1D Pregnancy \& Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CGM) data and insulin data). Through the collection of CGM, insulin, and pregnancy outcome data, the study will provide important information to understand how diabetes is being managed during pregnancy. These data will provide much needed evidence to guide modern management of diabetes during pregnancy with a goal of improving care and outcomes.
Type 1 diabetes (T1D) management during pregnancy is a critical area as pregnancy complicated by T1D is still associated with a markedly elevated risk of maternal and fetal complications. Because the risk of these complications is tightly linked to glucose levels, guidelines recommend lower glycemic targets than in non-pregnant individuals to optimize pregnancy outcomes. Hybrid closed loop (HCL) insulin delivery systems may aid in glycemic management during pregnancy, but options for use of HCL during pregnancy are limited and present challenges as systems are not approved for use in pregnancy and do not target pregnancy glycemic goals. Thus, pregnant individuals with T1D and their clinicians must consider off-label use of HCL systems with suboptimal glycemic targets. To get closer to pregnancy glycemic targets, individuals may adjust the way they use the system, but there is insufficient evidence to understand the impact of HCL systems available in the US on pregnancy glycemic metrics and pregnancy outcomes. To address these gaps in evidence, we propose an observational study that will enable systematic assessment of HCL system use in pregnancies complicated by T1D. The focus of this study is to assess glycemic outcomes measured by continuous glucose monitors and clinical pregnancy outcomes associated with use of HCL versus other insulin delivery methods. Data collected from this study will provide important information about how individuals in the United States are managing their diabetes during pregnancy and will help us to identify factors that could minimize the risk of diabetes-associated pregnancy complications and reduce the burden that comes with managing T1D in pregnancy. Pregnant individuals throughout the United States will be enrolled in this remote observational study. Participants will be asked to share details about their diabetes and pregnancy. Participants will also be asked to share diabetes device data from their continuous glucose monitor (CGM). Participants who use an insulin pump or connected insulin pen may also be asked to share these data.
Study Type
OBSERVATIONAL
Enrollment
500
Hybrid closed loop insulin delivery system is a system that uses a continuous glucose monitor (CGM) to send blood glucose values to an insulin pump that automatically provides insulin based on the blood glucose value and anticipated future level.
University of Alabama at Birmingham
Birmingham, Alabama, United States
RECRUITINGBarbara Davis Center for Diabetes & University of Colorado Health
Aurora, Colorado, United States
RECRUITINGJaeb Center for Health Research
Tampa, Florida, United States
RECRUITINGIndiana University
Indianapolis, Indiana, United States
RECRUITINGMass General Brigham
Boston, Massachusetts, United States
RECRUITINGJoslin Diabetes Center
Boston, Massachusetts, United States
RECRUITINGIcahn School of Medicine at Mount Sinai
New York, New York, United States
RECRUITINGThe Ohio State University
Columbus, Ohio, United States
RECRUITINGOregon Health and Science University
Portland, Oregon, United States
RECRUITINGHospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
RECRUITINGCGM Outcome (BG 63-140 mg/dl)
Percentage of time spent with glucose 63-140 mg/dl
Time frame: Up to 37 weeks gestation
CGM Outcome (BG<63 mg/dl)
Percentage time spent with glucose \<63 mg/dl
Time frame: Up to 37 weeks gestation
CGM Outcome (BG<54 mg/dl)
Percentage time spent with glucose \<54 mg/dl
Time frame: Up to 37 weeks gestation
CGM Outcome (BG>140 mg/dl)
Percentage time spent with glucose \>140 mg/dl
Time frame: Up to 37 weeks gestation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.